Form 4: Q32 Bio Director Receives Stock Options

Q32 Bio director David S. Grayzel was granted 16,363 stock options as part of his compensation, vesting quarterly.

Summary

• Director David S. Grayzel of Q32 Bio Inc. (QTTB) was granted 16,363 stock options on January 15, 2026.
• The options have an exercise price of $3.6 per share and are set to expire on January 14, 2036.
• This grant was made under the 2024 Stock Option and Incentive Plan and the company's non-employee director compensation policy.
• The options represent Grayzel's election to receive equity compensation in lieu of cash retainer fees.
• Vesting will occur in four equal quarterly installments, contingent on his continued service through each vesting date.
• The initial reporting of this option award was delayed due to an administrative oversight.
• Proceeds from any sale of shares upon exercise of these options will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims Section 16 ownership except for his pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine compensation disclosure, slightly positive for director alignment, but notes the administrative oversight in reporting and the specific arrangement regarding the proceeds.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value.
• The compensation structure, including equity in lieu of cash, is a common practice to conserve cash and incentivize performance.

Negatives

• An administrative oversight led to a delay in the initial reporting of the option award.
• The arrangement for proceeds to be transferred to Atlas Venture Life Science Advisors, LLC, and the disclaimer of Section 16 ownership, suggests a complex beneficial ownership structure.

Risks

• Administrative oversights in reporting, if not promptly corrected, could lead to compliance issues or questions regarding transparency.

Future Outlook

The options will vest in four equal quarterly installments as of the last date of each calendar quarter, contingent on the director's continued service, indicating future equity accumulation for the director.

Management Comments

• This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy.
• This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees.
• Due to administrative oversight this option award initially was not reported.
• The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Industry Context

StockSavvy.ai notes that equity compensation for non-employee directors is a common practice in the biotechnology and pharmaceutical sectors, aligning director interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• Equity grants for non-executive directors are standard across industries, including biotech, to incentivize long-term commitment and performance.
• The vesting schedule of four equal quarterly installments is a common approach to retain directors over a period.
• The election to receive stock options in lieu of cash retainer fees is also a common practice, particularly in growth-oriented companies, to conserve cash and further align interests.

Corporate Governance

Related Party Transactions

• Proceeds from any sale of shares upon exercise of the option will be transferred to Atlas Venture Life Science Advisors, LLC.
• The reporting person disclaims ownership for Section 16 purposes, except for his pecuniary interest, suggesting a relationship with Atlas Venture Life Science Advisors, LLC.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with long-term shareholder value through equity compensation.
• Director (David S. Grayzel): Receives equity compensation in lieu of cash, subject to vesting and continued service.
• Atlas Venture Life Science Advisors, LLC: Will receive proceeds from the sale of shares upon option exercise, indicating a financial interest in the director's compensation.

Next Steps

• The options will vest in four equal quarterly installments as of the last date of each calendar quarter.
• The director's continued service is required for the options to vest.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is an expected part of corporate governance and director incentive alignment. While there was an administrative oversight in reporting, the transaction itself does not present new material information that would significantly alter the investment thesis for Q32 Bio Inc. The arrangement where proceeds go to a third party (Atlas Venture Life Science Advisors, LLC) is noted but does not fundamentally change the company's operational or financial outlook. Therefore, a 'hold' recommendation is appropriate as this filing does not provide a strong catalyst for either buying or selling the stock.

Keywords

Q32 Bio, QTTB, Form 4, stock option, director compensation, equity grant, insider transaction, David S. Grayzel